Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd
* Says it and JCR Pharmaceuticals Co Ltd jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia
* In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin
* Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed
Source text in Japanese: goo.gl/eXovsF
Further company coverage: (Beijing Headline News)
 